Optimal selection of systemic therapy in older adults with psoriasis can be challenging, due
to sparse evidence-based guidance. This multicentre retrospective study investigated the …

Background Psoriasis patients over 65 years‐old (elderly) constitute a growing group,
underrepresented in clinical trials, and likely to be more prone to adverse events. Objective …

Importance Treating older adults with psoriasis can be challenging owing to comorbidities,
concomitant medication use, and consequent safety risks. Although many studies focus on …

Background Psoriasis is a common inflammatory disease in any age group, but also in older
patients (≥ 65 years of age). Since older patients are often excluded from clinical trials …

Background. Patients with moderate‐to‐severe psoriasis are often treated with systemic
immunosuppressant agents that decrease immune system function. For the elderly, these …

Background Psoriasis is a disease that often requires prolonged systemic treatment. It is
important to determine the safety of available therapies. There is currently little insight into …

Background Little is known about the adverse events (AE s) that lead to suspension of
systemic treatments for psoriasis in clinical practice. Objective The study aimed to …

Objective To describe the use of systemic therapy for psoriasis (biologic and nonbiologic
[classic] drugs) in patients not adequately represented in randomized controlled trials …

With our aging population, an increasing number of psoriasis patients are classified as
elderly. However, psoriasis treatment in older adults can be challenging, given an increased …

Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate
data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains …